Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Department of Oncology, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10 mg/kg) in combination with sunitinib 25-50 mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1 mo, respectively. Two patients experienced exacerbation of their preexisting hypertension; there were no grade 4 toxicities. The bevacizumab-sunitinib combination in sunitinib-refractory patients seems active and has a tolerable toxicity profile.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on